Annual EBITDA
-$235.37 M
-$106.23 M-82.27%
December 31, 2023
Summary
- As of February 22, 2025, VRDN annual EBITDA is -$235.37 million, with the most recent change of -$106.23 million (-82.27%) on December 31, 2023.
- During the last 3 years, VRDN annual EBITDA has fallen by -$125.40 million (-114.03%).
- VRDN annual EBITDA is now -480236.73% below its all-time high of -$49.00 thousand, reached on December 31, 2013.
Performance
VRDN EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBITDA
-$75.56 M
-$11.30 M-17.59%
September 30, 2024
Summary
- As of February 22, 2025, VRDN quarterly EBITDA is -$75.56 million, with the most recent change of -$11.30 million (-17.59%) on September 30, 2024.
- Over the past year, VRDN quarterly EBITDA has dropped by -$28.63 million (-61.01%).
- VRDN quarterly EBITDA is now -26117.56% below its all-time high of $290.40 thousand, reached on December 31, 2013.
Performance
VRDN Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBITDA
-$253.41 M
-$28.63 M-12.74%
September 30, 2024
Summary
- As of February 22, 2025, VRDN TTM EBITDA is -$253.41 million, with the most recent change of -$28.63 million (-12.74%) on September 30, 2024.
- Over the past year, VRDN TTM EBITDA has dropped by -$38.32 million (-17.82%).
- VRDN TTM EBITDA is now -606151.20% below its all-time high of -$41.80 thousand, reached on March 31, 2013.
Performance
VRDN TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBITDA Formula
EBITDA = Net Income + Interest + Taxes + Depreciation + Amortization
VRDN EBITDA Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -82.3% | -61.0% | -17.8% |
| 3 y3 years | -114.0% | -61.0% | -17.8% |
| 5 y5 years | -646.0% | -61.0% | -17.8% |
VRDN EBITDA Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -196.8% | at low | -194.5% | at low | -219.4% | at low |
| 5 y | 5-year | -477.6% | at low | -1313.8% | +16.5% | -764.0% | at low |
| alltime | all time | <-9999.0% | at low | <-9999.0% | +16.5% | <-9999.0% | at low |
Viridian Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$75.56 M(+17.6%) | -$253.41 M(+12.7%) |
| Jun 2024 | - | -$64.25 M(+34.4%) | -$224.78 M(+4.4%) |
| Mar 2024 | - | -$47.81 M(-27.3%) | -$215.29 M(-8.5%) |
| Dec 2023 | -$235.37 M(+82.3%) | -$65.79 M(+40.2%) | -$235.37 M(+9.4%) |
| Sep 2023 | - | -$46.92 M(-14.3%) | -$215.09 M(+9.3%) |
| Jun 2023 | - | -$54.77 M(-19.3%) | -$196.85 M(+14.9%) |
| Mar 2023 | - | -$67.88 M(+49.1%) | -$171.36 M(+32.7%) |
| Dec 2022 | -$129.13 M(+62.9%) | -$45.52 M(+58.7%) | -$129.13 M(+14.8%) |
| Sep 2022 | - | -$28.68 M(-2.1%) | -$112.52 M(+15.0%) |
| Jun 2022 | - | -$29.28 M(+14.1%) | -$97.86 M(+13.1%) |
| Mar 2022 | - | -$25.65 M(-11.3%) | -$86.52 M(+9.0%) |
| Dec 2021 | -$79.29 M(-27.9%) | -$28.91 M(+106.3%) | -$79.34 M(-43.7%) |
| Sep 2021 | - | -$14.01 M(-21.9%) | -$140.95 M(+6.6%) |
| Jun 2021 | - | -$17.94 M(-2.9%) | -$132.28 M(+9.7%) |
| Mar 2021 | - | -$18.48 M(-79.6%) | -$120.61 M(+9.7%) |
| Dec 2020 | -$109.97 M(+169.9%) | -$90.51 M(+1593.7%) | -$109.97 M(+274.9%) |
| Sep 2020 | - | -$5.34 M(-14.9%) | -$29.33 M(-16.1%) |
| Jun 2020 | - | -$6.28 M(-19.9%) | -$34.94 M(-6.2%) |
| Mar 2020 | - | -$7.83 M(-20.7%) | -$37.26 M(-8.6%) |
| Dec 2019 | -$40.75 M(+29.2%) | -$9.88 M(-9.9%) | -$40.75 M(-0.3%) |
| Sep 2019 | - | -$10.96 M(+27.4%) | -$40.89 M(+5.8%) |
| Jun 2019 | - | -$8.60 M(-24.1%) | -$38.66 M(+0.4%) |
| Mar 2019 | - | -$11.32 M(+13.1%) | -$38.49 M(+22.0%) |
| Dec 2018 | -$31.55 M | -$10.01 M(+14.8%) | -$31.55 M(+14.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2018 | - | -$8.72 M(+3.4%) | -$27.65 M(+12.3%) |
| Jun 2018 | - | -$8.43 M(+92.4%) | -$24.63 M(+5.4%) |
| Mar 2018 | - | -$4.38 M(-28.3%) | -$23.37 M(-9.5%) |
| Dec 2017 | -$25.82 M(+108.4%) | -$6.12 M(+7.3%) | -$25.82 M(+2.5%) |
| Sep 2017 | - | -$5.70 M(-20.6%) | -$25.20 M(+18.5%) |
| Jun 2017 | - | -$7.17 M(+4.9%) | -$21.27 M(+28.6%) |
| Mar 2017 | - | -$6.84 M(+24.4%) | -$16.54 M(+33.5%) |
| Dec 2016 | -$12.39 M(+12.6%) | -$5.50 M(+210.7%) | -$12.39 M(+26.4%) |
| Sep 2016 | - | -$1.77 M(-27.4%) | -$9.80 M(-11.8%) |
| Jun 2016 | - | -$2.44 M(-9.4%) | -$11.12 M(-0.1%) |
| Mar 2016 | - | -$2.69 M(-7.6%) | -$11.12 M(+1.1%) |
| Dec 2015 | -$11.00 M(+63.7%) | -$2.91 M(-5.6%) | -$11.00 M(+6.7%) |
| Sep 2015 | - | -$3.08 M(+26.0%) | -$10.31 M(+16.8%) |
| Jun 2015 | - | -$2.44 M(-4.8%) | -$8.83 M(-3.6%) |
| Mar 2015 | - | -$2.57 M(+15.7%) | -$9.16 M(+36.2%) |
| Dec 2014 | -$6.72 M(>+9900.0%) | -$2.22 M(+38.7%) | -$6.72 M(+59.5%) |
| Sep 2014 | - | -$1.60 M(-42.4%) | -$4.21 M(+45.8%) |
| Jun 2014 | - | -$2.77 M(+2018.3%) | -$2.89 M(+1991.4%) |
| Mar 2014 | - | -$131.00 K(-145.1%) | -$138.20 K(+182.0%) |
| Dec 2013 | -$49.00 K(-98.7%) | $290.40 K(-205.7%) | -$49.00 K(-85.6%) |
| Sep 2013 | - | -$274.70 K(+1099.6%) | -$339.40 K(+424.6%) |
| Jun 2013 | - | -$22.90 K(-45.2%) | -$64.70 K(+54.8%) |
| Mar 2013 | - | -$41.80 K | -$41.80 K |
| Dec 2012 | -$3.88 M | - | - |
FAQ
- What is Viridian Therapeutics annual EBITDA?
- What is the all time high annual EBITDA for Viridian Therapeutics?
- What is Viridian Therapeutics annual EBITDA year-on-year change?
- What is Viridian Therapeutics quarterly EBITDA?
- What is the all time high quarterly EBITDA for Viridian Therapeutics?
- What is Viridian Therapeutics quarterly EBITDA year-on-year change?
- What is Viridian Therapeutics TTM EBITDA?
- What is the all time high TTM EBITDA for Viridian Therapeutics?
- What is Viridian Therapeutics TTM EBITDA year-on-year change?
What is Viridian Therapeutics annual EBITDA?
The current annual EBITDA of VRDN is -$235.37 M
What is the all time high annual EBITDA for Viridian Therapeutics?
Viridian Therapeutics all-time high annual EBITDA is -$49.00 K
What is Viridian Therapeutics annual EBITDA year-on-year change?
Over the past year, VRDN annual EBITDA has changed by -$106.23 M (-82.27%)
What is Viridian Therapeutics quarterly EBITDA?
The current quarterly EBITDA of VRDN is -$75.56 M
What is the all time high quarterly EBITDA for Viridian Therapeutics?
Viridian Therapeutics all-time high quarterly EBITDA is $290.40 K
What is Viridian Therapeutics quarterly EBITDA year-on-year change?
Over the past year, VRDN quarterly EBITDA has changed by -$28.63 M (-61.01%)
What is Viridian Therapeutics TTM EBITDA?
The current TTM EBITDA of VRDN is -$253.41 M
What is the all time high TTM EBITDA for Viridian Therapeutics?
Viridian Therapeutics all-time high TTM EBITDA is -$41.80 K
What is Viridian Therapeutics TTM EBITDA year-on-year change?
Over the past year, VRDN TTM EBITDA has changed by -$38.32 M (-17.82%)